EUVIMEDEUVIMED entdecken
Editorial

Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic

Stefan Agewall iD

European Heart Journal - Cardiovascular Pharmacotherapy · 2024

DOI: 10.1093/ehjcvp/pvae061 ↗

Kurz gefasst

Editorial in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Stefan Agewall. Beteiligte Einrichtung: Editor-in-Chief. Hauptthemen laut MEDLINE: Hypolipidemic Agents. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypolipidemic AgentsHumansDyslipidemiasPharmacogenomic TestingTreatment OutcomeCardiovascular DiseasesLipidsPharmacogenomic VariantsPredictive Value of TestsGenetic TestingPharmacogeneticsHydroxymethylglutaryl-CoA Reductase InhibitorsClinical Decision-MakingPrecision Medicine

Substanzen

Hypolipidemic AgentsLipidsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Editor-in-Chief.
  • Institute of Clinical Sciences, Karolinska Institute of Danderyd, Stockholm, Sweden.

ORCID-Profile: Stefan Agewall

Zitieren

APA

Agewall, S. (2024). Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae061

Vancouver

Agewall S. Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae061

BibTeX
@article{Agewall2024,
  author = {Agewall, Stefan},
  title = {Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  doi = {10.1093/ehjcvp/pvae061}
}
Kostenlos starten →